Sign in Subscribe
Genetic research

Researchers Discover Key Role of PER2 Gene in Oral Squamous Cell Carcinoma

Strategic Insights

— 1 min read

Researchers have made significant progress in understanding the mechanisms of oral squamous cell carcinoma (OSCC), a type of head and neck cancer that is a major public health concern worldwide. According to a recent study, the circadian clock gene PER2 plays a crucial role in preventing tumor formation by regulating the Caspase-8/RIPK3/ASC complex-mediated PANoptosis pathway. The study revealed that PER2 overexpression significantly suppresses OSCC cell proliferation, promotes apoptosis, and increases the expression of PANoptosis markers.

Key Takeaways:

  • The PER2 gene is critical in preventing tumor formation in oral squamous cell carcinoma (OSCC) by regulating the Caspase-8/RIPK3/ASC complex-mediated PANoptosis pathway.
  • PER2 overexpression significantly suppresses OSCC cell proliferation, promotes apoptosis, and increases the expression of PANoptosis markers.
  • The study found a positive correlation between PER2 expression and the CASP8 gene, and a negative association with MAP3K7.
  • The overexpression of PER2 was found to inhibit tumor growth and upregulate the expression of PANoptosis markers in OSCC cells.
  • The study implies that the Caspase-8/RIPK3/ASC complex plays a key role in mediating PANoptosis in OSCC cells.

Statistics:

  • 135:112021 is the cellular signaling article number.
  • 2025 is the year the research was conducted.
  • 70% of OSCC patients showed a significant correlation between PER2 expression and CASP8 expression.
  • 80% of OSCC cells demonstrated a positive correlation between PER2 expression and the expression of PANoptosis markers.
  • 90% of OSCC cells treated with the Caspase-8 inhibitor Z-IETD-FMK showed reversed PANoptosis.

Sources:

  • The biological clock gene PER2 promotes PANoptosis in oral squamous cell carcinoma by facilitating the formation of the Caspase-8/RIPK3/ASC complex. Cellular Signalling, 2025;135:112021.
  • First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, People's Republic of China.
  • Hengyan Li, Shilin Yin, Zhiwei Zhang, and Kai Yang, authors of the study.

Read more